Joint Press Release
WADA-JADA-FPMAJ Cooperation to Advance the Fight against Doping in Sport
26 June 2013

The World Anti-Doping Agency (WADA), the Japan Anti-Doping Agency (JADA) and theFederation of Pharmaceutical Manufacturers’ Association of Japan (FPMAJ) signed a
Joint Declaration on Cooperation in the Promotion of Anti-Doping Activity &Development of Integrity of Sport for the promotion of anti-doping activity anddevelopment of integrity of sport in Tokyo, Japan earlier today.
The Declaration was signed by Mr. Kazuhiro Hayashi, Director of WADA Asia/Oceania
Regional Office, Prof. Hidenori Suzuki, President of JADA and Mr. Haruo Naito, Presidentof the FPMAJ. Also in attendance were Mr. Teru Fukui, Minister in charge of Sports &WADA Executive Committee member and Dr. Ichiro Kono, President of the Japan SportCouncil.

From left to right: Prof. Hidenori Suzuki, President of JADA; Mr. Haruo Naito, President of FPMAJ;
Mr. Kazuhiro Hayashi, Director of WADA Asia/Oceania Regional Office.

1

Mr. David Howman, Director General of WADA, sent a video message to welcome thecooperation, and highlighted the importance of the agreement. “We are very pleased
that JADA and FPMAJ haveagreed to this cooperation
at what is an importanttime in the fight against
doping in sport,” said
Howman.
“A crucial part of WADA’s
strategy is to develop
partnerships withorganizations that have theexpertise to identify
medicinal substances that
could be of interest todopers. This, in turn, will
help facilitate much fasterdevelopment of detection
methods in the context of doping in sport. We see this as a win-win collaboration, andwe look forward to a long, successful relationship,” he added.
Mr. Teru Fukui, Minster in charge of Sports and WADA Executive Committee member,attended the signage meeting and sent the government’s strong support to thepartnership between WADA, JADA and FPMAJ. He stressed: “I am delighted to see thispartnership developed and I would like to send my gratitude to all three partners fortheir commitment to the global development of anti-doping activity through this Joint
Declaration.”
The Declaration aims for JADA, WADA and FPMAJ to share the recognition that doping isboth a public health and significant societal issue. It is hoped the agreement will help
develop the integrity of sport by allowing member associations and companies of FPMAJ
to cooperate with WADA and JADA.
The cooperation aims to convey information regarding medicines with possible doping
potential, identify potential doping compounds at an early stage of clinical trials anddevelop research projects on detection under a confidentiality agreement amongst theparties’ volunteer bases. In cooperation with WADA, JADA effectively promotes andprovides the latest information on anti-doping for stakeholders.
In echoing David Howman’s words, Prof. Suzuki said: “We are very happy to see thejoint effort achieved with WADA and FPMAJ, with our stronger commitment in theprotection and development of the spirit of sport. Recognising doping as a public health2issue, we hope to establish a collaborative partnership with WADA and FPMAJ bysharing information effectively. We wish to ensure that this joint declaration will createa sporting environment where we can respect sport integrity across society.”
Mr. Naito commented: “Our mission as the pharmaceutical industry is to create hopefor patients and consumers through the provision of medicines. We feel a great sense ofregret that medicines developed to benefit patients could potentially be used for doping,
and also recognize that this a public health issue. We believe that by using theinformation and analytical methods we have available we can play a vital role in theprevention of such misuse. The pharmaceutical industry will help promote anti-doping
activity through this new collaborative partnership between the FPMAJ, WADA andJADA.”In July 2010, WADA and the International Federation of Pharmaceutical Manufacturersand Associations (IFPMA), of which President was Mr. Haruo Naito at the time, signed
the Joint Declaration on Cooperation in the Fight against Doping in Sport. Since theDeclaration, WADA has developed partnerships with the pharmaceutical andbiotechnology industries, which will provide expertise in finding solutions on doping anderadicating drug abuse.
WADA strongly supports further cooperation between JADA and the PharmaceuticalIndustry in Japan, and expects the new cooperation to promote and broaden an early
warning system practiced in successful bilateral collaborative exercises between WADA
and individual pharmaceutical companies at both national and regional levels.

3

About WADA
The World Anti-Doping Agency (WADA) is the international independent organization
created in 1999 to promote, coordinate and monitor the fight against doping in sport in
all its forms. The Agency is composed and funded equally by the sports movement andgovernments of the world. Its key activities include scientific research, education,
development of anti-doping capacities and monitoring of the World Anti-Doping Code –the first document harmonizing regulations regarding anti-doping in all sports and all
countries.
http://www.wada-ama.org/

About JADA
The Japan Anti-Doping Agency (JADA) was founded in 2001 as the cooperative effort ofall stakeholders in Japan. Supported by the Ministry of Education, Culture, Sports,
Science and Technology (MEXT), JADA endeavours to lead the anti-doping activity withits key activity areas of education, awareness raising, research, doping control and theJADA Sports Pharmacist Program. It strives to promote and strengthened a value-based
education program in Japan in view of development of people and society through sport.
http://www.playtruejapan.org/

About FPMAJ
The Federation of Pharmaceutical Manufacturers’ Associations of JAPAN (FPMAJ) is theonly umbrella organisation for all pharmaceutical industry in Japan and contributes theintegrity of pharmaceutical industry and the health of citizen. FPMAJ is composed of 14
Pharmaceutical Industry Associations including JPMA (Japan PharmaceuticalManufacturers Association) and other specific pharmaceutical industry associations suchas Home medicine, OCT, Generic drugs and others mainly at national level and 17Regional (Prefectural) Associations covering almost over Japan. Their main activities
include examination on the common issues of the pharmaceutical industry, proposal on
the policies to the related authorities, improvement of the quality of medicines, rawmaterial, standard, production, distribution and promotion of international cooperation.
Recently FPMAJ is growing their interest and commitment to the public health concern,
the misuse problems of their products and the fight against doping in sport effectively.
http://www.fpmaj.gr.jp/4

JOINT DECLARATION ON COOPERATION IN THE PROMOTION OF ANTI-DOPINGACTIVITY &DEVELOPMENT OF INTEGRITY OF SPORT

Japan Anti-Doping Agency, World Anti-Doping Agency &The Federation of Pharmaceutical Manufacturers’ Associations of JAPANPreamble
Doping in sport is against the spirit of fair play and brings the unfair advantage tothe fair competition in sport and also causes the significant risk in health of the dopedathletes. These threats today can affect not only among the elite athletes but also
among students and amateur and occasional athletes.
Anti-Doping activity is to respect the fundamental core value of sport and it isessential to flourish the real sporting activity under the universally agreed principle.
Moreover, those enriched values flourished through sporting activity are common
values and principles in society. In view of this, doping is considered as a public healthissue.
It has become imperative to prevent the abuse and misuse of sport-related drugs
and to establish a collaborative relationship between the international and national
governmental and non-governmental agencies for their mutual benefit.
Therefore, the collaborative efforts between a pharmaceutical agency and an antidoping agency is aspired regarding the prevention in the risk of misuse of medicineswith doping potential and identify potential doping compounds at an early stage ofclinical trials, as well as the development of research in detection methods. In July 2010,
the World Anti-Doping Agency (WADA) and the International Federation ofPharmaceutical Manufacturers and Associations (IFPMA) signed "Joint Declaration onCooperation in the Fight against Doping in Sport” (Japan Pharmaceutical Manufacturers
Association (JPMA) under The Federation of Pharmaceutical Manufacturers’ Associationsof JAPAN (FPMAJ) is a major member association of IFPMA).

5

ScopeThe Japan Anti-Doping Agency (JADA) strives to develop people and society throughsport and to protect and develop the core value of sport that essentially celebrates thehuman potential reached. In close collaboration with WADA, the government, sport
movement and all stakeholders, JADA endeavours to lead anti-doping activity in orderto foster a society where the real champion is valued.
The Federation of Pharmaceutical Manufacturers’ Associations of JAPAN (FPMAJ) isthe umbrella organisation for all pharmaceutical industry in Japan and contributes theintegrity of pharmaceutical industry and the health of citizen. Therefore, FPMAJ is
committed to support the development of anti-doping activity.
The World Anti-Doping Agency (WADA) supports this collaboration and cooperation
between JADA and FPMAJ to effectively promote the anti-doping activity.

Objective
JADA, WADA and FPMAJ share the recognition that doping is a public health issue anda significant societal issue. They contribute to the development of integrity of sport
though the cooperation against doping.
Those member associations and companies of FPMAJ participate in this collaboration
through providing information on the prescription or non-prescription drug with doping
potential and on detection technology to prevent abuse of doping compounds underdevelopment on their volunteer bases. They cooperate with JADA and WADA as
followings:
1. Those member associations and companies of FPMAJ, except those of the membersof The Japan Pharmaceutical Manufacturers Association (JPMA) and already have orwish to have collaboration or agreement directly with WADA, convey information
only via a contact person designated by the parties regarding the medicines with thepossible doping potential and identify potential doping compounds at an early stageof clinical trials, as well as the development of research in detection methods.
Protection of any proprietary or confidential information will be achieved by meansof a confidentiality agreement and not shared with any third parties, unless mutuallyagreed in writing. Based on the confidentiality principle, JADA shares theinformation with WADA.
2. To develop anti-doping activity as part of public health matter, JADA in cooperation
with WADA effectively promotes and provides the latest information on anti-doping
not only to elite athletes and their entourage but also to those specialised inpharmacology and those engaged in the development of medicines as well as to theresearcher engaged in the development of analytical methods. FPMAJ and its
member associations support and cooperate with these activities.
6Herein, WADA, JADA and FPMAJ declare to establish the collaborative relations to thepromotion of anti-doping and flourish the spirit and core value of sport.

This Declaration enters immediately into force upon signature by the representativesof these three organisations, below:

7